Micafungin
A semisynthetic echinocandin lipopeptide antifungal that inhibits fungal 1,3-beta-D-glucan synthase, FDA approved on March 16, 2005 as Mycamine for esophageal candidiasis and Candida prophylaxis in stem cell transplant recipients, with candidemia and pediatric indications added later.
Also referenced as: Micafungin sodium, FK463, FK-463, Mycamine, Funguard
Also appears in: Immune
Public product evidence No certificate records are bound to a tracked Micafungin product page A record counts here only when a vendor publishes a certificate against one of its own tracked Micafungin product pages. Other certificates naming this compound may still exist — search the wider certificate database.This compound maps to at least one regulated medical product or label context in the United States.
Primary research area: Other. Also surfaces under Immune for browsing and discovery.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
Micafungin sodium, FK463, FK-463, Mycamine, Funguard
FDA label signal · 74 trials · 1000 PubMed results
Micafungin is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.
Micafungin has 46 name-matched clinical trials (highest phase: Phase 4) and 1000 PubMed-indexed publications and holds an FDA drug label. 5 trials have posted results. Note: 1 retracted publication in the literature.
Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Micafungin?
Micafungin is a semisynthetic lipopeptide antifungal of the echinocandin class: a cyclic hexapeptide core carrying a lipophilic side chain that anchors the molecule at the fungal membrane next to its target enzyme. Fujisawa Pharmaceutical developed it as FK463 from FR901379, an acylated cyclic hexapeptide produced by the fungus Coleophoma empetri F-11899; the natural product’s fatty acyl chain is removed enzymatically and replaced chemically with an optimized N-acyl side chain, and a sulfate group on the ring makes micafungin water-soluble, the feature that distinguishes it from the other echinocandins (Hashimoto, Journal of Antibiotics, 2009;62(1):27–35). The US label gives micafungin sodium the molecular formula C56H70N9NaO23S and a formula weight of 1,292.26, supplied as the monosodium salt.
Micafungin was the second echinocandin approved anywhere after caspofungin, approved in Japan as Funguard in October 2002 and in the United States as Mycamine on March 16, 2005. Anidulafungin and rezafungin are later members of the class with their own approvals; all four share the target and scaffold but are distinct molecules. Micafungin is a hospital antifungal for serious Candida infections, given only by intravenous infusion, with essentially no footprint in the research-peptide market.
How it works
- Inhibition of 1,3-beta-D-glucan synthase. The US label states that micafungin inhibits the synthesis of 1,3-beta-D-glucan, an essential component of the fungal cell wall that is not present in mammalian cells, and that isolates with reduced susceptibility carry mutations in the FKS protein of the glucan synthase complex; micafungin is a potent inhibitor of this enzyme (Hashimoto, Journal of Antibiotics, 2009;62(1):27–35).
- Fungicidal against Candida, fungistatic against Aspergillus. In the original in vitro characterization, FK463 had MICs of 0.0039 µg/mL or lower to 2 µg/mL against Candida species and 0.0039 to 0.0313 µg/mL against Aspergillus species, killed 99% of Candida albicans within 24 hours at concentrations above 0.0156 µg/mL, retained activity against azole-resistant strains, was fungistatic against Aspergillus fumigatus, and had no activity against Cryptococcus neoformans, Trichosporon species or Fusarium solani; 4% human serum albumin raised MICs more than 32-fold (Tawara et al., Antimicrobial Agents and Chemotherapy, 2000;44(1):57–62).
- Non-cytochrome metabolism and fecal elimination. Micafungin is more than 99% protein bound and is metabolized by arylsulfatase and catechol-O-methyltransferase with only minor CYP-mediated hydroxylation; 71% of a radiolabeled dose is recovered in feces, and the label’s pharmacokinetic table reports mean terminal half-lives of 13.4 to 14.5 hours in adult patients with invasive candidiasis. Moderate hepatic dysfunction did not change weight-adjusted clearance and severe renal dysfunction did not alter the pharmacokinetics (Hebert et al., Journal of Clinical Pharmacology, 2005;45(10):1145–1152).
- Mild CYP3A inhibition with a few partner drugs. In 27 healthy volunteers, micafungin lowered the apparent oral clearance of cyclosporine from 645 to about 540 mL/h/kg, a mild inhibition of cyclosporine metabolism (Hebert et al., Journal of Clinical Pharmacology, 2005;45(8):954–960). The label also flags higher sirolimus, itraconazole and nifedipine exposures.
Research status
Esophageal candidiasis, the first approved indication. A dose-response trial in 245 HIV-positive adults found endoscopic cure rates of 68.8%, 77.4% and 89.8% with micafungin 50, 100 and 150 mg daily, the pooled 100 and 150 mg result (83.5%) comparable to fluconazole 200 mg (86.7%) (de Wet et al., Clinical Infectious Diseases, 2004;39(6):842–849). The pivotal noninferiority trial randomized 523 patients to micafungin 150 mg or fluconazole 200 mg daily: endoscopic cure was 87.7% versus 88.0%, 84.8% versus 88.7% remained recurrence-free four weeks after treatment, and drug-related adverse events occurred in 27.7% versus 21.3% (de Wet et al., Alimentary Pharmacology and Therapeutics, 2005;21(7):899–907).
Prophylaxis in hematopoietic stem cell transplantation. A randomized, double-blind phase 3 trial run with the National Institute of Allergy and Infectious Diseases Mycoses Study Group compared micafungin 50 mg daily with fluconazole 400 mg daily during neutropenia in 882 adult and pediatric transplant recipients. Success, meaning no suspected, proven or probable invasive fungal infection through therapy and no proven or probable infection through four weeks of follow-up, was 80.0% versus 73.5% (difference 6.5%; 95% CI 0.9% to 12%; P = 0.03), the first randomized demonstration of an echinocandin as prophylaxis (van Burik et al., Clinical Infectious Diseases, 2004;39(10):1407–1416).
Candidemia against liposomal amphotericin B (NCT00106288). A double-blind, multinational noninferiority trial randomized 264 adults to micafungin 100 mg daily and 267 to liposomal amphotericin B 3 mg/kg daily as first-line therapy. Per-protocol treatment success, both clinical and mycological response at the end of therapy, was 89.6% versus 89.5% (stratified difference 0.7%; 95% CI −5.3 to 6.7), with fewer treatment-related adverse events and discontinuations on micafungin (Kuse et al., Lancet, 2007;369(9572):1519–1527). In the pediatric substudy of 98 children, success was 72.9% versus 76.0% (adjusted difference −2.4%; 95% CI −20.1 to 15.3), with discontinuations for adverse events in 3.8% versus 16.7% (Queiroz-Telles et al., Pediatric Infectious Disease Journal, 2008;27(9):820–826).
Head-to-head against caspofungin. An international, double-blind trial randomized 595 adults with invasive candidiasis to micafungin 100 mg daily, micafungin 150 mg daily or standard-regimen caspofungin. Success at the end of blinded intravenous therapy was 76.4%, 71.4% and 72.3%, with no differences in mortality, relapse or adverse events, so both micafungin regimens were noninferior (Pappas et al., Clinical Infectious Diseases, 2007;45(7):883–893). Supplement S-008, approved on January 22, 2008, added candidemia, acute disseminated candidiasis and Candida peritonitis and abscesses to the US label.
Invasive aspergillosis, never a US indication. In an open-label, non-comparative multinational study, 225 patients with panel-confirmed invasive aspergillosis received micafungin alone or with another systemic antifungal; the favorable response rate at the end of therapy was 35.6%, the micafungin-only groups were small (6 of 12 primary, 9 of 22 salvage), and 56.1% of all 326 micafungin-treated patients died during therapy or six weeks of follow-up (Denning et al., Journal of Infection, 2006;53(5):337–349). The Japanese label covers Aspergillus as well as Candida infections; the US and EU labels do not.
Pediatric and neonatal development. Supplement S-015, approved on June 21, 2013, added pediatric patients 4 months of age and older to all three indications. A phase 3, double-blind noninferiority trial in infants aged 2 to 120 days with proven invasive candidiasis (NCT00815516) compared micafungin 10 mg/kg daily with amphotericin B deoxycholate; it was terminated for slow recruitment after 30 infants, and fungal-free survival one week after the last dose was 12 of 20 (60%) versus 7 of 10 (70%) (Benjamin et al., Pediatric Infectious Disease Journal, 2018;37(10):992–998). FDA reviewers combined these limited data with nonclinical candidemia models to support labeling in infants younger than 4 months (Taormina et al., Clinical Infectious Diseases, 2021;73(12):2335–2340); supplement S-023, approved on December 20, 2019, added treatment of candidemia and related infections without meningoencephalitis or ocular dissemination in that age group, and the label states that safety and effectiveness have not been established when the central nervous system or eye is involved.
Regulatory path. Funguard for infusion was approved in Japan in October 2002. Drugs@FDA lists two applications for Mycamine, NDA 021506 and NDA 021754, both approved on March 16, 2005 for esophageal candidiasis and prophylaxis of Candida infections in hematopoietic stem cell transplant recipients. The European Commission authorized Mycamine on April 25, 2008; because of liver tumors in rats, the Committee for Medicinal Products for Human Use restricted it to patients for whom other antifungals are not appropriate, and the EU product information carries a boxed warning. Drugs@FDA now lists Astellas’s Mycamine vials as discontinued, with a Federal Register determination that the discontinuation was not for safety or effectiveness reasons; the first generic micafungin was approved on May 17, 2019, the most recent abbreviated application on March 17, 2026, and Baxter’s premixed micafungin in sodium chloride under NDA 216142 on September 29, 2023. As of November 2026, no new micafungin indication is pending at the FDA.
The liver-tumor question. The US label has no boxed warning but reports hepatic carcinomas and adenomas in rats given micafungin for 6 months at exposures 8 times the highest recommended human dose. A US cohort of 23,220 propensity-matched hospitalized patients treated between 2005 and 2012 and followed through 2016 recorded ten hepatocellular carcinoma deaths in 71,285 person-years, one among 6,903 micafungin recipients and nine among 16,317 comparator antifungal users (hazard ratio 0.29; 95% CI 0.04 to 2.24) (Schneeweiss et al., Journal of Antimicrobial Chemotherapy, 2020;75(1):221–228).
Common dosage forms
- Mycamine for injection. Single-dose vials of lyophilized micafungin sodium containing 50 mg or 100 mg of micafungin, for intravenous infusion in a hospital setting; the Astellas brand vials are listed as discontinued in the US.
- Generic micafungin for injection. The same 50 mg and 100 mg single-dose lyophilized vials, marketed under a dozen abbreviated applications and administered intravenously by clinicians.
- Micafungin in sodium chloride premixed bags. Baxter’s ready-to-infuse 1 mg/mL solution in 50 mg, 100 mg and 150 mg single-dose containers for intravenous use.
- Funguard for infusion. The Japanese presentation, in 25 mg, 50 mg and 75 mg vials of micafungin sodium for intravenous use only.
- No other presentation. No oral, inhaled or topical micafungin product exists.
Key considerations
- Regulatory status. The FDA Approved status reflects the March 16, 2005 approval of Mycamine (micafungin sodium) for injection under NDA 021506 and NDA 021754 for esophageal candidiasis and prophylaxis of Candida infections in hematopoietic stem cell transplant recipients. Supplements added candidemia (January 22, 2008), pediatric use from 4 months (June 21, 2013) and infants under 4 months (December 20, 2019). The Astellas brand vials are listed as discontinued for reasons other than safety or effectiveness, and generic and premixed micafungin remain on the US market.
- A lipopeptide, not a classical peptide drug. Micafungin is a fermentation-derived cyclic hexapeptide with a synthetic side chain and a sulfate group, given only intravenously and acting on a fungal cell-wall enzyme with no human counterpart; it is unrelated in origin and pharmacology to the hormone and signaling peptides of the research-peptide market.
- The rat liver tumor signal divides regulators. The same 6-month rat data produced a boxed warning and a last-line restriction in the European Union but only a warnings-and-precautions entry in the United States. The one large human cohort found hepatocellular carcinoma mortality below 0.2 per 1,000 person-years with micafungin and with comparator antifungals, too few events to confirm or exclude a small excess risk.
- Candida spectrum with class-wide resistance. Micafungin is fungicidal against most Candida species but fungistatic against Aspergillus, inactive against Cryptococcus, Trichosporon and Fusarium, and subject to FKS mutations that reduce susceptibility to every echinocandin; it has no US or EU indication for aspergillosis despite the Japanese label.
- Class siblings are not aliases. Caspofungin, anidulafungin and rezafungin share the echinocandin scaffold and target but are different molecules with separate approvals and labels; micafungin, micafungin sodium, FK463, Mycamine and Funguard all denote the same compound.